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Intradermal injection of substance P elicits an itch
sensation in human subjects and an itch-associated
response in mice. The substance P-induced itch-
associated response in mice is not inhibited by anti-
histamine. Therefore, the mechanisms of substance
P-induced itch-associated response are unclear. In
this study, we demonstrated one of the mechanisms.
Substance P induces an arachidonate cascade to
produce prostaglandins and leukotriene. In this study
we considered whether arachidonate metabolites are
involved in the substance P-induced itch-associated
response. A phospholipase A2 inhibitor arachidoryl-
tri¯uoromethyl ketone inhibited the substance P-
induced itch-associated response in mice. Pre-
treatment with the glucocorticoids betamethasone
and dexamethasone also produced inhibition of the
substance P-induced itch-associated response in mice
as well as humans. The 5-lipoxygenase inhibitor
zileuton, but not the cyclooxygenase inhibitors
indomethacin and diclofenac, suppressed substance
P-induced itch-associated response. The leukotriene
B4 receptor antagonist 5-[2-(2-carboxyethyl)-3-{6-(4-
methoxyphenyl)-5E-hexenyl}oxyphenoxy]valeric acid
produced inhibition, whereas pranlukast (leukotriene
C4/D4/E4 receptor antagonist) and 5(Z)-7-[1S,2S,
3S,5R-3-(trans-b-styren)sulfonamido-6,6-dimethylbi-
cyclo(3,1,1)hept-2-yl]-5-heptenoic acid (EP1 receptor
antagonist) were without effect. Furthermore, when
the production of leukotriene B4 and prostaglandin
E2 was measured in skin injected with substance P
and in mouse keratinocytes applied with substance
P, the level of both products increased. As leuko-
triene B4, but not prostaglandin E2, also induces the
itch-associated response in mice, these results suggest
that leukotriene B4 and keratinocytes, cutaneous cells
which produced leukotriene B4, play an important
role in substance P-induced itch-scratch response in
mice. Leukotriene B4 receptor antagonist and 5-
lipoxygenase inhibitor may be novel antipruritic
drugs. Key words: keratinocyte/leukotriene B4 receptor/
5-lipoxygenase/tachykinin NK1 receptor/WBB6F1 W/
Wv. J Invest Dermatol 117:1621±1626, 2001
I
tch is a skin sensation that provokes a desire to scratch. This
sensation accompanies various skin diseases (e.g., atopic
dermatitis, contact dermatitis, and urticaria) and several
systemic disorders (e.g., chronic renal failure and cholestasis).
H1 histamine receptor antagonists are the drugs of ®rst choice
for the treatment of itch, but many pruritic diseases except acute
urticaria respond poorly to the H1 receptor antagonists (Wahlgren,
1991). The precise mechanisms and mediators of itch in most
pruritic diseases are unclear.
When applied to the skin, substance P (SP) elicits an itch
sensation in human subjects (HaÈgermark et al, 1978; Barnes et al,
1986). This peptide is speculated to be involved in hemodialysis-
associated pruritus (Kaku et al, 1990) and the pruritus of atopic
dermatitis (Heyer et al, 1991) and psoriasis (Ellis et al, 1993). In
mice, SP elicits scratching behavior (Kuraishi et al, 1995; Andoh et
al, 1998). This response is suppressed by pretreatment with
naloxone, capsaicin, and compound 48/80 (Andoh et al, 1998).
Similarly, several kinds of human itching are alleviated by treatment
with naloxone (Summer®eld, 1980; Bernstein et al, 1982; Bergasa et
al, 1995) and capsaicin (ToÂth-KaÂsa et al, 1986; Wallengren, 1991;
Knight and Hayashi, 1994), and SP-induced itching is inhibited by
pretreatment with compound 48/80 (HaÈgermark et al, 1978).
These similarities suggest that SP-induced scratching behavior of
the mouse is an itch-associated response. SP is generally believed to
elicit itch through the release of histamine from mast cells. In
human subjects, the H1 histamine receptor antagonist chlorcycli-
dine inhibits an itch sensation induced by intradermal (i.d.)
injection of low, but not high, doses of SP (HaÈgermark et al,
1978). Intradermal SP releases histamine from human skin for
20 min, a duration that is longer than the duration of itching
(Barnes et al, 1986). In mice, an i.d. injection of SP elicits
itch-associated response in normal mice and mast-cell-de®cient
mice as well (Andoh et al, 1998). Neurokinin-1 (NK1) tachykinin
receptors are involved in the itch-associated response induced by
SP (Andoh et al, 1998), but not in the histamine release from mast
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cells (Mousli et al, 1990). These ®ndings taken together suggest that
mast-cell-dependent and independent mechanisms are involved in
SP-induced itch-associated response.
In human subjects, prostaglandin (PG) E2 is a weak pruritogen
(HaÈgermark and Strandberg, 1977) and prolongs experimentally
induced itch (HaÈgermark and Strandberg, 1977; Fjellner and
HaÈgermark, 1979). In addition, aspirin inhibits itching of patients
with polycythemia vera (Fjellner and HaÈgermark, 1979). In animal
experiments, although an i.d. injection of PGE2 alone does not
elicit itch-associated response (Andoh and Kuraishi, 1998), it
enhances itch-associated response induced by serotonin (unpub-
lished observation). On the other hand, an i.d. injection of
leukotriene (LT) B4 elicits apparent itch-associated response in
mice (Andoh and Kuraishi, 1998), although it shows only weak
effects at higher concentrations in mice (Andoh and Kuraishi, 1998)
and humans (Camp et al, 1983). Thus, it seems interesting to
examine whether the arachidonic acid cascade is involved in itch-
associated response induced by SP in mice.
MATERIALS AND METHODS
Animals Unless otherwise mentioned, we used male ICR mice
(Japan SLC, Shizuoka, Japan) of 5±6 wk of age. In some experiments,
mast-cell-de®cient mice (WBB6F1 W/Wv) were used at the age of
5 wk. They were housed under controlled temperature (23°C±25°C)
and light (lights on from 08:00 to 20:00) conditions. Food and water
were freely available. The experimental procedures for mice were
conducted in accordance with the guidelines of the Guiding Principles
for the Care and Use of Laboratory Animals approved by the Committee
for Animal Experiments in Toyama Medical and Pharmaceutical
University.
Drugs SP (Peptide Institute, Minoh, Japan) was dissolved in
physiologic saline. Diclofenac sodium, arachidoryltri¯uoromethyl ketone
(AACOCF3), cyclo(Gln-D-Trp(NMe)Phe(R)Gly[ANC-2]Leu-Met)2 (L-
668 169), and cyclo(Gln-Trp-Phe-Leu-Met) (L-659 877) were purchased
from Research Biochemicals International (Natick, MA) and dissolved in
physiologic saline. Dexamethasone, betamethasone, and indomethacin
were purchased from Sigma Chemical (St. Louis, MO) and suspended in
0.5% sodium carboxymethylcellulose solution. Zileuton, 5-[2-(2-
carboxyethyl)-3-{6-(4-methoxyphenyl)-5E-hexenyl}oxyphenoxy]valeric
acid (ONO-4057), and pranlukast (all from Ono Pharmaceutical, Osaka,
Japan) were suspended in 0.5% sodium carboxymethylcellulose solution.
5(Z)-7-[1S,2S,3S,5R-3-(trans-b-styren)sulfonamido-6,6-
dimethylbicyclo(3,1,1)hept-2-yl]-5-heptenoic acid (ONO-NT-012)
(Ono Pharmaceutical) was dissolved in equimoles of 1 N NaOH and
then diluted with tap water. The sodium salt of LTB4 (Ono
Pharmaceutical) was dissolved in physiologic saline. LTD4 was purchased
from Sigma (St. Louis) and dissolved in ethanol and then diluted with
physiologic saline. Fluo-3/AM and F-127 were purchased from Dojindo
(Kumamoto, Japan).
Behavioral experiments The hair was clipped over the rostral part
of the murine back the day before the experiment. Before behavioral
recording, the mice (four animals per observation) were put into an
acrylic cage (26 3 18 3 30 cm) composed of four cells
(13 3 9 3 30 cm) for at least 1 h for acclimation. Immediately after an
i.d. injection, the animals were put back in the same cells and their
behaviors were videotaped using an 8 mm video camera for 1 h with all
experimenters kept out of the observation room. Playing back of the
video served for counting scratching behavior. The mouse generally
scratches by the hind paws several times for about 1 s and a series of
these movements was counted as one bout of scratching (Kuraishi et al,
1995). SP, LTB4, and LTD4 were injected i.d. in a volume of 50 ml into
the interscapular part of the back. AACOCF3, L-668 169, and L-
659 877 were injected i.d. together with SP. Zileuton, ONO-4057,
pranlukast, dexamethasone, and betamethasone were administered
perorally 1 h before SP injection. Indomethacin, sodium diclofenac, and
ONO-NT-012 were administered perorally 30 min before SP injection.
Isolation of mouse keratinocytes The clipped, ethanol-sterilized
skin was isolated from the mouse that had been decapitated and bled.
After washing it with phosphate-buffered saline containing 100 U per ml
penicillin and 100 mg per ml streptomycin (PBS-PS), we removed
connective tissue from the isolated skin and cut the skin into pieces. The
pieces were washed twice with PBS-PS containing 0.02%
ethylenediamine tetraacetic acid (EDTA), and treated with 0.25% trypsin
dissolved in PBS-PS at 4°C for 6 h. The epidermis was carefully peeled
from the skin, and gently shaken in PBS-PS containing 0.02% EDTA at
room temperature until most epidermis preparations ¯oated up. The
¯oating preparations were passed through a stainless steel mesh with 40
mm pores and the ®ltrate was centrifuged at 150 3 g at 4°C for 5 min.
Precipitated cells were washed with 10 ml of Joklik-modi®ed minimum
essential medium containing 100 U per ml penicillin and 100 mg per ml
streptomycin (MEM-PS), suspended in MEM-PS containing 20 ng per
ml epidermal growth factor, 10 mg per ml insulin, and 10 ng per ml
bovine pituitary extract, and cultured at 37°C in air containing 5% CO2
until use.
Enzyme immunoassay The treated region of the skin (2 cm in
diameter) was isolated 5 min after injection and immediately put into
ice-chilled ethanol containing 10 mM indomethacin and 10 mM zileuton.
After homogenization and centrifugation (at 3000 rpm for 5 min) of the
skin sample, 2 ml of supernatant was diluted with 20 ml of ice-chilled
0.1 M acetic acid, applied to Bond Elute C2 column (Varian, MA), and
eluted with 3 ml ethyl acetate. After evaporation of the elutant, the
residue was suspended in 150 ml of 0.01 M sodium bicarbonate buffer
(pH 10.0), sonicated for 5 min, and then diluted with enzyme
immunoassay buffer (Cayman Chemical, Ann Arbor, MI) for the assays
of LTB4 and PGE2.
Primary cultures of the mouse keratinocytes were diluted by MEM-PS
to 1 3 106 cell per 400 ml well. Drugs were added to the culture
medium in a volume of 50 ml and then SP was added immediately
(vehicle, L-668 169 and L-659 877), or 30 min (indomethacin) or 1 h
later (dexamethasone and zileuton) in a volume of 50 ml. Samples were
taken from the supernatant 5 min after SP application and diluted with
enzyme immunoassay buffer (Cayman Chemical) for the assay. The
amount of LTB4 and PGE2 was determined using EIA kits (Cayman
Chemical).
Statistical analysis All data are presented as mean and SEM.
Statistical signi®cance was analyzed using the one-way analysis of
variance followed by Dunnett's multiple comparisons; p < 0.05 was
considered signi®cant.
RESULTS
Effects of phospholipase A2 inhibitor and glucocorticoids on
SP-induced itch-associated response An i.d. injection of SP
(100 nmol per site) elicited scratching of the skin around the
injected site by the hind paws in mice (Fig 1a); the total number of
responses by 1 h after injection was 75.7 6 14.4 (mean 6 SEM,
n = 8). When injected together with SP, the phospholipase A2
inhibitor AACOCF3 (Street et al, 1993) (10±100 nmol per site)
suppressed SP-induced itch-associated response in a dose-
dependent manner (Fig 1b). A 1 h pretreatment with
dexamethasone and betamethasone at peroral doses of 0.3±3 mg
per kg also suppressed the itch-scratch response induced by SP
(Fig 1c, d).
Effects of 5-lipoxygenase inhibitor and leukotriene receptor
antagonists on SP-induced itch-associated response We
examined the involvement of the 5-lipoxygenase pathway in the
itch-associated response induced by SP. The 5-lipoxygenase
inhibitor zileuton (Carter et al, 1991) at peroral doses of 10±
100 mg per kg produced a dose-dependent inhibition of the SP
action (Fig 2a). In addition, ONO-4057, an LTB4 receptor
antagonist (Kishikawa et al, 1991), at peroral doses of 10±100 mg
per kg also produced a dose-dependent inhibition of the SP action
(Fig 2b). On the other hand, the same doses of pranlukast, an
antagonist to cysteinyl LTs (Nakagawa et al, 1992), did not affect
the SP action (Fig 2c). In addition, i.d. injection of LTD4 did not
increase itch-associated response; the numbers of scratching
following LTD4 at doses of 0.01, 0.03, 0.1, and 0.3 nmol per site
were 27.4 6 3.5, 27.4 6 5.5, 28.9 6 8.5, and 14.4 6 2.9 per h
(mean 6 SEM, n = 8 each), respectively.
Effects of cyclooxygenase inhibitors and prostaglandin
receptor antagonist on SP-induced itch-associated
response We examined the involvement of the
cyclooxygenase pathway in the itch-associated response induced
by SP. The cyclooxygenase inhibitors indomethacin (1±10 mg per
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kg) and diclofenac sodium (3 and 10 mg per kg) did not inhibit the
itch-associated response induced by SP, but instead there were
increased tendencies (Fig 2d). In addition, ONO-NT-012, which
blocks EP1 PG receptors (Minami et al, 1995), did not affect the
SP-induced itch-associated response (Fig 2e).
Effect of LTB4 receptor antagonist on SP-induced itch-
associated response in mast-cell-de®cient mice When
injected intradermally, SP (100 nmol per site) elicited an apparent
itch-associated response with comparable potency in mast-cell-
de®cient mice (WBB6F W/Wv) (Fig 3). A 1 h pretreatment with
ONO-4057 at a peroral dose of 100 mg per kg markedly
suppressed SP-induced itch-associated response in mast-cell-
de®cient mice and control mice (Fig 3).
Contents of LTB4 and PGE2 in the skin An i.d. injection of
SP (100 nmol per site) produced a 2.9-fold increase in the
cutaneous content of LTB4, and this action was almost abolished by
AACOCF3 (100 nmol per site), dexamethasone (3 mg per kg), and
zileuton (100 mg per kg) (Fig 4a); these dosages suppressed SP-
induced itch-associated response (Figs 1b, c, 2a). The NK1
receptor antagonist L-668 169 at 50 nmol per site, a dose that
suppressed the SP-induced itch-associated response (Andoh et al,
1998), also abolished SP-induced increase in LTB4 content,
whereas indomethacin (10 mg per kg) was without effect (Fig 4a).
Figure 1. Inhibition of SP-induced itch-associated response by
phospholipase A2 inhibitor and glucocorticoids. (a) Time-course of
itch-associated response of the mouse after an intradermal injection of SP
(100 nmol per site). (b) The phospholipase A2 inhibitor AACOCF3
suppresses SP-induced itch-associated response. The inhibitor was
injected intradermally together with SP (100 nmol per site). (c, d)
Glucocorticoids suppress SP-induced itch-associated response.
Dexamethasone (c) and betamethasone (d) were administered perorally
1 h before the SP injection. Results (mean 6 SEM) are of eight animals.
*p < 0.05 compared with control (CN).
Figure 2. Effects of inhibition of eicosanoid
systems on SP-induced itch-associated
response. The mouse was given an i.d.injection
of SP (100 nmol per site) and scratching behavior
was counted for 1 h. (a) Zileuton, (b) ONO-
4057, and (c) pranlukast were administered
perorally 1 h before SP injection, and (d)
indomethacin, (d) diclofenac, and (e) ONO-NT-
012 were administered 30 min before. Results
(mean 6 SEM) are of eight animals. *p < 0.05
compared with control (CN).
Figure 3. Inhibition of SP-induced itch-associated response by
ONO-4057 in mast-cell-de®cient mice. SP (100 nmol per site) was
injected intradermally. ONO-4057 (100 mg per kg) was administered
perorally 1 h before SP injection. Results (mean 6 SEM) are of eight
animals. *p < 0.05 compared with control (CN).
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An i.d. injection of SP (100 nmol per site) produced a 2.5-fold
increase in the cutaneous content of PGE2 (Fig 4b). Although
AACOCF3 (100 nmol per site), dexamethasone (3 mg per kg), and
L-668 169 (50 nmol per site) inhibited this action, zileuton
(100 mg per kg) was without effect (Fig 4b). Indomethacin
(10 mg per kg) abolished the SP-induced production of PGE2
(Fig 4b).
Production of LTB4 and PGE2 in keratinocytes As mouse
keratinocytes responded to SP in the above experiments, we
examined whether SP would increase the production of LTB4 and
PGE2 in the keratinocytes. A bath application of SP in
concentrations of 1±10 mM to the primary cultures of mouse
keratinocytes increased the production of LTB4 in a concentration-
dependent manner, with a 2-fold increase at a concentration of
10 mM (Fig 5a). Such SP effect was abolished by pretreatment
with dexamethasone in concentrations of 1 and 10 mM. This effect
was also inhibited by pretreatment with zileuton (1 and 10 mM) in
a concentration-dependent manner, with complete inhibition at
10 mM, whereas indomethacin (1 and 10 mM) was without effect.
L-668 169 (1 and 10 mM) exerted a concentration-dependent
inhibition on the LTB4 production induced by SP, whereas the
NK2 receptor antagonist L-659 877 (1 and 10 mM) was without
effect.
SP (1 and 10 mM) also increased the production of PGE2 in the
mouse keratinocytes; the concentration of PGE2 following 10 mM
SP was 1.5 times that of untreated controls (Fig 5b). The SP action
was inhibited by L-668 169 (1 and 10 mM), but not by L-659 877
(1 and 10 mM). Dexamethasone and indomethacin at concentra-
tions of 1 and 10 mM inhibited PGE2 production, whereas zileuton
was without effect at the same concentrations (Fig 5b).
DISCUSSION
The phospholipase A2 inhibitor AACOCF3 at a dose that inhibited
SP-induced production of PGE2 and LTB4 markedly inhibited SP-
induced itch-associated response. The results show an important
role of the arachidonic acid cascade in SP-induced itching. In this
study, furthermore, we determined the role of 5-lipoxygenase and
cyclooxygenase pathways in the SP action. The LTB4 receptor
antagonist ONO-4057 markedly suppressed the itch-associated
response of the mouse to SP. In addition, SP markedly increased
the content of LTB4 in the skin at a dose that elicited itch-
associated response. LTB4 is a potent pruritogen; LTB4 at a dose of
0.03 nmol per site elicits about a hundred scratch bouts per hour
(Andoh and Kuraishi, 1998), which is comparable to the effect of
SP at a dose of 100 nmol per site. Taken together, these ®ndings
strongly suggest that LTB4 is involved in SP-induced itching in
mice. Zileuton selectively inhibited SP-induced increase in the
content of LTB4, but not PGE2, in the skin and markedly inhibited
itch-associated response following SP injection, a ®nding support-
Figure 4. The production of LTB4 and PGE2 after SP injection in
mouse skin. SP (100 nmol per site) and saline (SLN) were injected
intradermally and 5 min later the contents of LTB4 and PGE2 in the
treated skin were determined. AACOCF3 (ACF; 100 nmol per site) and
L-668 169 (L668; 50 nmol per site) were injected with SP.
Dexamethasone (DX; 3 mg per kg) and zileuton (ZLT; 100 mg per kg)
were administered perorally 1 h before SP injection, and indomethacin
(IND; 10 mg per kg) was 30 min before. Results (mean 6 SEM) are of
six animals. *p < 0.05 vs SLN; #p < 0.05 vs SP alone. NON,
nontreatment.
Figure 5. The SP-induced production of LTB4 and PGE2 in
mouse keratinocytes. SP (10 mM) was applied to the primary culture
of keratinocytes that had been isolated from mouse skin, and 5 min later
the supernatant was taken for the assay. Dexamethasone (DX) and
zileuton (ALT) were administered 1 h before SP, and indomethacin
(IND) 30 min before. L-668 169 (L668), L-659 877 (L659), and vehicle
(SP alone) was administered immediately before SP. Results (mean 6
SEM) are of six experiments. *p < 0.05 vs without SP; #p < 0.05 vs
10 mM SP alone.
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ing the view that LTB4 plays an important role in SP-induced
itching. In humans, LTB4 is increased in the lesioned skin of
patients with pruritic diseases such as atopic dermatitis and psoriasis
(Brain et al, 1984; Ruzicka et al, 1986). Pruritus of chronic
hemodialysis patients is alleviated by azelastin (Matsui et al, 1994;
Kanai et al, 1995), an agent that inhibits LTB4 receptor and LTB4
production. These ®ndings taken together suggest that the
suppression of LTB4 production is a mechanism of acute
antipruritic action of glucocorticoids and provide the possibility
that LTB4 receptors and 5-lipoxygenase are novel targets for the
development of antipruritic agents.
An i.d. injection of LTB4 at doses of 0.001±0.03 nmol per site
produces itch-associated response in a dose-dependent manner
(Andoh and Kuraishi, 1998), whereas LTD4 was without effect at
doses of 0.01±0.3 nmol per site (present experiments). In addition,
the cysteinyl LT antagonist pranlukast did not affect SP-induced
itch-associated response. LTD4 and LTC4 are not pruritogenic after
i.d. injection in human subjects (Camp et al, 1983). Therefore,
cysteinyl LT may not be pruritogenic at least in the skin.
An i.d. injection of SP increased the content of PGE2 in the skin.
Although indomethacin (10 mg per kg) abolished the SP-induced
increase in the cutaneous content of PGE2, it did not inhibit the
itch-associated response induced by SP. Similarly, diclofenac also
did not suppress the SP-induced itch-associated response, and the
EP1 receptor antagonist ONO-NT-012 was without effect. In
contrast, although zileuton markedly suppressed the SP-induced
itch-associated response, it did not affect the cutaneous production
of PGE2. Therefore, PGE2 may not play an important role in the
pruritogenic action of SP. The results are consistent with the effects
of aspirin-like agents on human itching; these agents generally do
not suppress experimental and dermatitis-induced itching (StaÊhle
and HaÈgermark, 1985; Daly and Shuster, 1986). An i.d. injection of
PGE2, however, elicits a mild itching in human subjects
(HaÈgermark and Strandberg, 1977; Fjellner and HaÈgermark,
1979). PGE2 increases serotonin-induced itching in human subjects
(Fjellner and HaÈgermark, 1979) and serotonin-induced itch-
associated response in mice (unpublished observation). In addition,
aspirin alleviates pruritus of patients with polycythemia vera
(Fjellner and HaÈgermark, 1979). Therefore, we do not exclude
the possibility of the involvement of PGE2 in the itching of some
pruritic diseases.
SP markedly increased the production of LTB4 and slightly
PGE2, both of which were abolished by the NK1 tachykinin
receptor antagonist. SP also increases [Ca2+]i in cultured mouse
keratinocytes (Koizumi et al, 1994). The results indicate that SP acts
directly on the NK1 receptors of the mouse keratinocytes to
produce eicosanoids, especially LTB4. Considering that the
keratinocytes are the largest cell group in the epidermis, the data
suggest that the epidermal keratinocytes are the primary site of the
LTB4-producing action of i.d. SP. The NK1 receptor antagonist L-
668 169 abolished the production of LTB4 in the skin and
keratinocytes, whereas the NK2 receptor antagonist L-659 877 was
without effect. These results are consistent with behavioral
experiments in which SP-induced itch-associated response was
markedly suppressed by L-668 169 but not by L-659 877 (Andoh
et al, 1998). Thus, the keratinocytes may play an important role in
the production of a pruritogenic mediator LTB4. The ability of
human keratinocytes to produce LTB4 is in dispute. Some workers
reported on 5-lipoxygenase expression in human keratinocytes
(Janssen-Timmen et al, 1995), whereas others have not found 5-
lipoxygenase (Breton et al, 1996). Human keratinocytes have LTA4
hydrolase activity, however (Ikai et al, 1994; Iversen et al, 1994),
and transform exogenous and polymorphonuclear-cell-derived
LTA4 into LTB4 (Iversen et al, 1994). Therefore, keratinocytes in
human epidermis may produce LTB4 under certain dermatitis
conditions. Cutaneous mast cells may release LTB4 (Harris et al,
1998). ONO-4057 signi®cantly inhibited SP-induced itch-associ-
ated response in mast-cell-de®cient mice, however. Therefore, the
mast cells may not be the primary source of pruritogenic LTB4 in
the epidermis. Thus, keratinocytes rather than mast cells may be
important target cells of antipruritic agents.
Itch signals may be mediated mainly by C ®bers (Schmelz et al,
1997). LTB4 sensitizes cutaneous C ®ber nociceptors (Martin et al,
1988). In addition, in our preliminary experiments, LTB4 increased
the concentration of intracellular Ca2+ ions in primary cultured
mouse dorsal root ganglion neurons, especially capsaicin-sensitive
neurons (unpublished observations); most C ®bers are sensitive to
capsaicin (Holzer, 1991). Repeated treatment with capsaicin cream
suppresses the itch of patients with pruritic diseases, such as chronic
renal failure with hemodialysis treatment (Breneman et al, 1992),
pruritic psoriasis (Ellis et al, 1993), notalgia paresthetica
(Wallengren, 1991), and hydroxyethylstarch-induced pruritus
(Szeimies et al, 1994). In addition, repeated treatment with
capsaicin inhibits experimental itch induced by histamine in
humans (ToÂth-KaÂsa et al, 1986) and itch-associated response
induced by SP in mice (Andoh et al, 1998). Thus, it is suggested
that itch is mediated by capsaicin-sensitive primary afferents.
Therefore, LTB4 produced by SP-stimulated keratinocytes (and the
other cutaneous cells) might act directly on primary afferent
terminals to produce itch signals.
Glucocorticoids suppressed SP-induced itch-associated response.
Considering that glucocorticoids suppress the production of
arachidonic acid metabolites by inhibiting phospholipase A2
(Piltch et al, 1989), these results raised the possibility that the
inhibitory action of glucocorticoids on the SP action was
substantially due to the inhibition of the arachidonic acid cascade.
Recently, however, it has been reported that glucocorticoids
regulate the expression of cyclooxygenase-2, but not cycloox-
ygenase-1 (Zhang et al, 1999). In this study, treatment with
glucocorticoids 1 h before the SP application inhibited the
production of LTB4 and PGE2 in murine skin and keratinocytes.
Although the detail of the mechanisms is unknown from this study,
these results suggest that the acute action(s) of glucocorticoids may
include the inhibition of enzyme activities including phospholipase
A2. Furthermore, we examined whether dexamethasone has the
antagonistic activity of LTB4 receptors. Dexamethasone (3 mg per
kg) markedly suppressed both itch-associated response and LTB4
production induced by SP, whereas it did not affect the LTB4-
induced itch-associated response (unpublished observation).
Therefore, the inhibition of the production, rather than the action,
of LTB4 may be responsible for the suppressive action of
dexamethasone on itch-associated response. Thus, the inhibition
of the production of LTB4 may be involved in the inhibitory effect
of glucocorticoids on SP-induced itch-associated response.
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